What would happen if the essential drugs were suddenly more expensive, and Europe would start to lose control over their own pharmaceutical production? It’s not just a scenario, but a reality that takes shape on the Washington-Brussels axis. The intention of the Trump administration to impose 25% customs tariffs on the pharmaceutical products imported into the US has mobilized the industry and European authorities.
Photo archive
The European Union is now in front of a strategic choice: fight for autonomy or accept the reality of a global market in which the rules are written across the ocean? In Romania, the authorities say they are carefully pursuing the situation to avoid a crisis of essential drugs.
Will health become a luxury?
What does this mean to patients? In 2023, the EU had a significant commercial surplus in the pharmaceutical sector compared to the United States, with exports of about 92 billion euros and imports of about 40 billion euros. This difference emphasizes the importance of the commercial relationship between the two parties in the field of pharmaceuticals. Because Europe is still a major drug exporter to the US – in 2023, exports were valued at 90 billion euros. If the US suddenly adds a 25% fee to these products, prices increase, and European citizens – especially from less rich countries, such as Romania – will pay more for vital treatments.
The big companies will decide that it is more financially advantageous to produce medicines in the US and will move their production and research centers there. In fact, the industry has already put pressure on the European Commission: “Either you help us, or we leave!” The pharmaceutical giants – Pfizer, Eli Lilly, Astrazeneca – sent a harsh message to the European Commission. In an open letter, they demand less bureaucracy and more flexible regulations, financial aid for research and development, support for local production of innovative drugs and eliminate new ecological taxes.
What is the risk of Europe and by default, Romania
If this “pharmaceutical exodus” takes shape, the effects can be harsh:
– Price increases in imported drugs
– risk of shortage in future pandemic or seizures
– Decreasing innovation in Europe
– a greater US addiction in the sanitary field
– an increasingly obvious polarization between the western and east countries.
What vital drugs might undergo price changes
A dramatic impact could be felt in particular in the case of oncological treatments such as Keytruda and Opdivo, whose price could increase by up to 2,500 euros a month, immunotherapies such as Humira (used in autoimmune diseases), as well monthly. In Romania, where many of these treatments are either partially compensated or purchased directly by patients, the effect could be double: pressure on the budget of the National Health Insurance House and the restriction of patients to innovative therapies. Also, essential vaccines, such as those against HPV or meningitis, may suffer significant increases and delays in delivery.
Romania, with a sanitary system anyway fragile and a small budget, would be among the first hit.
Romania’s position
The Romanian authorities have not issued a hard official position so far, but sources from the Ministry of Health claim that “response scenarios” are analyzed to protect strategic stocks.
A possible response? Consolidation of local production and diversifying the import of drugs.
C -on -running negotiations between Brussels and Washington
The European press talks about reaching a compromise at European level. Brussels has discussions with the US administration in an attempt to avoid effective imposition of tariffs or to get exemptions for certain categories of pharmaceuticals. Although the differences in commercial vision between the US and the EU are deep, both parties have said they want a negotiated solution that does not affect patients access to essential treatments.
For now, we are not talking about certainties, but about strategic risks and calculations. But one thing is clear: health cannot become a exchange currency in a commercial game.
